Jennifer Leeds
Antibacterial drug hunter and life-science business development leader
Emeryville, California
Summary
Deep expertise in antibacterial drug discovery and translational research — led discovery teams and co-invented LFF571 and contributed to LYS228, with multiple peer-reviewed publications examining mechanism of action, resistance, and effects on toxin production. nih+2
Business development and partnering leader on the West Coast — transitioned from discovery leadership into BD&L roles at Novartis, leading search and evaluation activities across the western US and Canada and supporting in-licensing and out-licensing efforts. novartis+1
Active mentor, board member/observer, and reviewer in the life-science ecosystem — has served on corporate boards and as board observer, participates in mentor programs (QB3), and serves on scientific selection and review boards (Novo Holdings REPAIR Impact Fund SSB, Innosuisse). qb3+2
Strong academic and publication record in microbiology and infectious disease — holds a PhD in medical microbiology and immunology, completed a postdoctoral fellowship at Harvard Medical School, and authored numerous primary research articles, review articles, book chapters, and patents. harvard+2
Work
Education
Projects
Writing
Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile
January 1, 2015Reports that subinhibitory concentrations of LFF571 decrease toxin A and B levels in C. difficile cultures and compares effects with fidaxomicin, vancomycin, and metronidazole.
Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571
January 1, 2012Describes LFF571's mechanism (inhibition of translation via elongation factor Tu) and genetic basis of reduced susceptibility in C. difficile; supports development of LFF571 as a treatment for C. difficile infection.
WO2007106670A2 - N-formyl hydroxylamine compounds (patent)
September 20, 2007Patent listing naming Jennifer Leeds as an inventor on compounds (N-formyl hydroxylamine derivatives) useful as antimicrobials and peptidyl deformylase inhibitors.